StreetInsider.com News Articles

Jade Biosciences (JBIO) PT Raised to $55 at H.C. Wainwright

Tue, 02 Jun 2026 06:55:59 -0400

(Updated - June 2, 2026 6:55 AM EDT)

H.C. Wainwright analyst Arthur He raised the price target on Jade Biosciences (NASDAQ: JBIO) to $55.00 (from $45.00) while maintaining a Buy rating.

The analyst commented: "On June 1, 2026, Jade Biosciences, our 2026 Top Pick, reported strong Phase 1 results for JADE101, its next-generation anti-APRIL mAb for IgA nephropathy (IgAN). The first-in-human study was a randomized, double-blind, placebo-controlled single-ascending-dose trial in healthy volunteers (HVs). As of the data cutoff of April 14, 2026, 32 participants were randomized 6:2 active-to-placebo across four cohorts (175 mg, 350 mg, 700 mg, and 1400 mg), each receiving

Jade Biosciences (JBIO) PT Raised to $55 at H.C. Wainwright

Tue, 02 Jun 2026 06:55:59 -0400

(Updated - June 2, 2026 6:55 AM EDT)

H.C. Wainwright analyst Arthur He raised the price target on Jade Biosciences (NASDAQ: JBIO) to $55.00 (from $45.00) while maintaining a Buy rating.

Jade Biosciences (JBIO) PT Raised to $74 at BTIG

Mon, 01 Jun 2026 11:23:59 -0400

BTIG analyst Julian Harrison raised the price target on Jade Biosciences (NASDAQ: JBIO) to $74.00 (from $39.00) while maintaining a Buy rating.

The analyst comments "We believe the stock weakness today likely represents an attractive buying opportunity; the data are fundamentally strong, in our view. We are raising our PT to $74 from $39 after raising our probability of success for JADE101 in IgAN to 75%, increasing peak penetration to 20% from 13%, and accelerating launch to late 2029 from 2032. JADE101's Phase 1 HV results land well into our previewed blue-sky scenario, with strong potential for best-in-disease efficacy and Q12W

Jade Biosciences (JBIO) PT Raised to $74 at BTIG

Mon, 01 Jun 2026 11:23:59 -0400

BTIG analyst Julian Harrison raised the price target on Jade Biosciences (NASDAQ: JBIO) to $74.00 (from $39.00) while maintaining a Buy rating.

Jade Biosciences (JBIO) PT Raised to $47 at Guggenheim

Mon, 01 Jun 2026 10:45:25 -0400

Guggenheim analyst Vamil Divan raised the price target on Jade Biosciences (NASDAQ: JBIO) to $47.00 (from $32.00) while maintaining a Buy rating.

Form 8-K Jade Biosciences, Inc. For: Jun 01

Mon, 01 Jun 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260601/26579354.html

Form 8-K Jade Biosciences, Inc. For: Jun 01

Mon, 01 Jun 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260601/26579354.html

Jade Biosciences reports interim phase 1 results for IgA nephropathy drug

Mon, 01 Jun 2026 07:00:56 -0400

Jade Biosciences Inc. (NASDAQ: JBIO) reported interim results from a Phase 1 trial of JADE101, an experimental treatment for immunoglobulin A nephropathy, showing approximately 70% reductions in IgA levels sustained at 12 weeks after a single dose.

The San Francisco-based biotechnology company said the trial enrolled 32 healthy volunteers across four dose groups, with participants receiving single subcutaneous doses ranging from 175 mg to 1,400 mg. The drug targets APRIL, a protein involved in producing pathogenic IgA in patients with the kidney disease.

According to the company's projections, a maintenance dosing schedule of 350 mg every 12 weeks following an initial 700

Jade Biosciences reports interim phase 1 results for IgA nephropathy drug

Mon, 01 Jun 2026 07:00:56 -0400

According to the company's projections, a maintenance dosing schedule of 350 mg every 12 weeks following an initial 700

Jade Biosciences reports interim phase 1 results for IgA nephropathy drug

Mon, 01 Jun 2026 07:00:56 -0400

According to the company's projections, a maintenance dosing schedule of 350 mg every 12 weeks following an initial 700

Jade Biosciences reports interim phase 1 results for IgA nephropathy drug

Mon, 01 Jun 2026 07:00:56 -0400

According to the company's projections, a maintenance dosing schedule of 350 mg every 12 weeks following an initial 700

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

Mon, 01 Jun 2026 07:00:00 -0400

~70% IgA reductions sustained at 12 weeks after a single dose of JADE101
>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeks
IgA-lowering effect observed to be faster, deeper, and more durable than with first-generation anti-APRIL or dual APRIL/BAFF agents
JADE101 was well-tolerated across all evaluated doses
Phase 2 clinical trial in patients with IgA nephropathy underway, with interim clinical data expected in 2027
Phase 3 registrational trial expected to be initiated in the first half of 2027
Company to host a webcast and conference call today at 8:00 a.m. ET